Replies to post #22594 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

Lt, you seem to think that I am against screening. That is not true. I would love to see effective screening for cancer that finds the truly dangerous fast growing cancers.

The current cancer markets do not meet that criteria. The fact is that a lot of experts think that the PSA test causes a lot of unnecessary procedures. Given that fact, RECAF would cause even more unnecessary procedures.

If you have not noticed, RECAF is not receiving any support from the medical community nor from any cancer organization. It is not that it is unknown. Moro has been hyping it for years and even managed to talk Abbott into a license agreement. Thus far, it is confirmed that Abbott has not even paid the feasibility milestone and nothing has been heard from Inverness.

Two other companies that have attempted to commercialize universal markers have failed miserably. Does that tell you anything about the prospects of even another universal marker?

If there was any support for universal markers, neither of those companies would be going broke and BioCurex would not be selling for ten cents and expecting massive dilution. It is absolutely insane for an investor to put more money in a failing technology.

[Gold Seeker]

LT, biocurex is not in trouble just because of Smithline. The inability to pay the loan is just a symptom that the technology is not viable. If Abbott thought RECAF had value, they would have proceeded and the loan would not be a problem.

If Abbott had taken RECAF into trials, do you really think that the stock would be selling for ten cents? Do you think investors would be facing massive dilution?

If RECAF was viable as a commercial test, do you not think that cancer organizations would not be praising the expected value of being tested? None of this is happening. The only people you find hyping the value of RECAF are a few current investors, stock promoters and Moro.